A biotech superstar with UNTHSC roots
By Jan Jarvis
Six years ago in an acceleration lab at UNT Health Science Center, the co-founders of ZS Pharma were developing a drug that they believed held great promise. But even with such lofty expectations, ZS Pharma co-founders Alvaro Guillem and Jeff Keyser may have underestimated their biotech startup’s potential.
Earlier this month British drug maker AstraZeneca agreed to acquire ZS Pharma for $2.7 billion in cash.
In the pharmaceutical world – where it typically takes a decade or more to move a drug from bench to bedside – ZS Pharma has moved at lightning speed. UNT Health Science Center helped make it all possible by providing offices, conference rooms and a lab where much of the work was done, Guillem said.
“During the early years it was critical to have the support of institutions like UNTHSC and the accelerator labs to be able to move the project forward,” Guillem said. “To this day, we continue to collaborate with labs and rely on their equipment and expertise to address various technical topics.”
From the start, ZS Pharma had all the making of a biotech superstar. Founded in 2008, it debuted on Wall Street as the first biotech IPO in Texas since 2000. Its drug, called ZS-9, has been on the fast track from the start.
Multiple clinical trials have shown the effectiveness of the drug, which is expected to hit the market in 2016. It treats hyperkalemia, a potentially life-threatening disease caused by excess potassium. About one in 200,000 people have the condition, which often affects people with chronic kidney disease and chronic heart failure.
Since 2006, UNT Health Science Center’s Office of Research Development and Commercialization and TECH Fort Worth, a non-profit technology incubator, have worked in partnership to bring new technologies to the market.
Firms get a boost from the UNTHSC Accelerator Lab Program along with the Executives-in-Residence, who act as mentors and offer advice from their years of experience in the pharmaceutical industry.
Taking research to the marketplace can be an arduous process. Playing a part in getting this drug on the path to patients has been rewarding for everyone involved , said Lawrence “Joe” Allred, Associate Vice President for Research and Innovation at UNTHSC.
“We can rightfully take pride in ZS Pharma’s success as a graduation of incubation in our Accelerator Labs,” he said.
By Alex Branch Student government presidents and vice presidents from every osteopathic medical school in the United States will convene at UNT Health Science Center for their annual national meeting. It’s the first time in 15 years that UNTHSC’s Texas College of Osteopathic Medi...Read more
Jan 15, 2019
By Alex Branch Robert Richard, DO, told UNT Health Science Center medical student Sarah Hmaidan exactly what she should expect from him as her preceptor. “He told me if he wasn’t inspiring me to be the best doctor I could be or challenging me to see the whole patient, then he was...Read more
Jan 10, 2019
By Alex Branch A generous estate gift from a longtime community volunteer whose family was impacted by dementia will establish a $3 million endowed chair to support groundbreaking research into Alzheimer’s disease and other translational research projects at UNT Health Science Center. Si...Read more
Jan 8, 2019
By Alex Branch J. Glenn Forister, PhD, PA-C, believes in the value of high-performing teams, and that’s what he sees at UNT Health Science Center. The institution’s One University concept, values-based culture and focus on extraordinary teamwork are concepts that led Dr. Forister to accept...Read more
Jan 7, 2019